Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Showcasing Advancements in Breast Cancer Risk Assessment and Treatment
Myriad Genetics (NASDAQ: MYGN) presented new data at the 2022 San Antonio Breast Cancer Symposium, focusing on a spotlight discussion regarding breast cancer risk prediction. The discussion covered a study involving 130,058 women, highlighting the use of a combined risk score based on polygenic risk scores and the Tyrer-Cuzick model. The findings aim to enhance breast cancer prevention and screening strategies. Myriad showcased various products, including MyRisk, MyChoice CDx, and EndoPredict, emphasizing their role in personalized cancer care.
- None.
- None.
- Spotlight discussion highlights how combined risk score may lead to improved breast cancer prevention and screening strategies.
SALT LAKE CITY, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN) a leader in genetic testing and precision medicine, today announced multiple presentations of new data at the 2022 San Antonio Breast Cancer Symposium (SABCS), including a spotlight discussion on breast cancer risk prediction.
“Genetic testing is an essential tool across the continuum of breast cancer care, enabling physicians to provide guidance about a woman’s individual risk and helping them make personalized treatment recommendations upon diagnosis,” said Thomas Slavin, M.D., chief medical officer, Myriad Genetics. “The data we’re presenting demonstrates our ongoing commitment to advancing scientific research to improve patient outcomes and delivering products that provide timely, data-driven medical information to support equitable care for all women.”
Myriad Data at SABCS 2022
Spotlight Discussion: PD14-05 - Prospective longitudinal validation of a breast cancer risk prediction model in a cohort of 130,058 women
Date: Thursday, Dec. 8, 2022, 5:00 PM - 6:15 PM (CST)
Presenter: Brent Mabey, MSc, Biostatistician II, Myriad Genetics
Done in collaboration with researchers from multiple clinics and universities, this study assessed how looking at polygenic risk score (PRS) for women of diverse ancestries, while using ancestry-informative genetic markers combined with version 7 of the Tyrer-Cuzick model, generates a combined risk score that can help predict breast cancer risk.
Poster Session: P2-03-23 - Retrospective evaluation of outcomes in a real-world, prospective cohort using EndoPredict®: Results from the Charité registry
Date: Wednesday, Dec. 7, 2022, 7:00 AM - 8:15 AM (CST).
Presenters: Prof. Carsten Denkert, Director Institute of Pathology, University Hospital Marburg, Germany.
Done in collaboration with Charité University Hospital Berlin and University Hospital Marburg, this study conducted an evaluation of patient outcomes in a prospective cohort using EndoPredict.
Additionally, there will also be poster session (P6-01-24) about an independent EndoPredict study from Klinikum rechts der Isar, Technical University of Munich, Germany, on Friday, Dec. 9 from 7:00-8:15 a.m. CST. The study looked at prospective long-term outcome data with EndoPredict for women with early-stage breast cancer.
Poster Session: P5-03-03 - Variant Classification Discordance: A real-world experience of genetic test results in a community-based setting
Date: Thursday, Dec. 8, 2022, 5:00 PM - 6:15 PM (CST)
Presenter: Shelly Cummings, M.S., C.G.C., Vice President of Oncology Medical Affairs, Myriad Genetics
This study was conducted in collaboration with Ascension Illinois and provides a look into the real-world experience of genetic testing results that help to accurately classify hereditary cancer germline genetic variants for appropriate care.
Among the Myriad products highlighted in the company’s SABCS exhibit are:
- MyRisk™ with RiskScore®, Myriad’s market-leading hereditary cancer test that offers the first polygenic breast cancer risk assessment for women of all ancestries. RiskScore delivers a personalized 5-year and lifetime risk for developing breast cancer for women who qualify for MyRisk.
- MyChoice® CDx is the first and only FDA-approved tumor test that determines HRD status using BRCA status and Genomic Instability Status.
- BRACAnalysis CDx® is the only FDA-approved test used to rapidly identify patients with germline BRCA1 and BRCA2 mutations who may be eligible for certain targeted therapies.
- EndoPredict is a breast cancer prognostic test that helps to accurately determine an individual patient’s 15-year risk of distant recurrence to help physicians identify which patients may consider safely forgoing chemotherapy.
- Precise™ Oncology Solutions provides a streamlined ordering experience that gives providers the ability to receive summarized results for comprehensive germline testing, tumor profiling and companion diagnostic options, including HRD testing.
Follow Myriad on Twitter via @myriadgenetics and keep up to date with SABCS meeting news and updates by using the #SABCS22 hashtag.
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. Fast Company named Myriad among the World’s Most Innovative Companies for 2022. For more information, visit www.myriad.com.
Myriad, the Myriad logo, BRACAnalysis, BRACAnalysis CDx, Colaris, Colaris AP, MyRisk, Myriad MyRisk, MyRisk Hereditary Cancer, MyChoice CDx, Prequel, Prequel with Amplify, Amplify, Foresight, Precise, FirstGene, SneakPeek, Health.Illuminated., RiskScore, Prolaris, UroSuite, GeneSight, and EndoPredict are trademarks or registered trademarks.
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company’s products and commitment to advancing scientific research to improve patient outcomes and delivering products that provide timely, data-driven medical information to support equitable care for all women. These “forward-looking statements” are based on management’s expectations of future events as of the date hereof and are subject to a number of known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 25, 2022, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.
| Media Contact: | Investor Contact: |
| Megan Manzari | Matt Scalo |
| (385) 318-3718 | (801) 584-3532 |
| Megan.Manzari@myriad.com | Matt.Scalo@myriad.com |
FAQ
What is the focus of Myriad Genetics' presentation at the 2022 San Antonio Breast Cancer Symposium?
What innovative product did Myriad Genetics highlight at SABCS 2022?
When did Myriad Genetics present their findings at SABCS 2022?
What study did Myriad Genetics conduct related to breast cancer risk?
What is the significance of the combined risk score discussed by Myriad Genetics?
